Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTHOUSE: rhPSMA-7.3 (18F) PET in Newly Diagnosed Prostate Cancer
NCT04186819Phase 3Completed
- Sponsor
- Blue Earth Diagnostics
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by Blue Earth Diagnostics. Primary endpoints: Specificity of rhPSMA-7.3 (18F) PET for detecting N1 disease at Day 1 and Sensitivity of rhPSMA-7.3 (18F) PET for detecting N1 disease at Day 1. Started Mar 2020; status: completed.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04186819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186819.